CTLA4 and neoplasm: These activated CD4+ T-regulatory cells express CTLA-4(35) and PD-1, two immune-inhibitory checkpoint molecules that downregulate T-cell immune responses (37), leading to tumor development (68), and contributing to cell growth (69).